MediSix Therapeutics
About MediSix Therapeutics
MediSix Therapeutics Pte Ltd is an early-stage cell therapy company that is taking a novel approach to develop chimeric antigen receptor (“CAR”) T cells to target T cell lymphoma and leukemia. The company was founded by Dario Campana, M.D. PhD. with initial investment from Lightstone Singapore, L.P., a Singapore-focused fund founded in 2016 by Lightstone Ventures.YEAR FOUNDED:
2016
LEADERSHIP:
Founder: Dario Campana, M.D. PhD.
2 articles about MediSix Therapeutics
-
Twist Bioscience Signs Antibody Discovery Collaboration with MediSix Therapeutics to Develop T-cell Therapies
4/7/2022
Twist Bioscience Corporation and MediSix Therapeutics today announced a collaboration to discover novel antibodies against five undisclosed targets.
-
MediSix Signs Exclusive Licensing Agreement With The National University of Singapore (NUS)
9/12/2017